基蛋生物：南京爱基本次减持计划实施完毕，累计减持约67万股

Core Viewpoint - The company,基蛋生物, has reported a complete reliance on in vitro diagnostics for its revenue in 2024, indicating a focused business model in this sector [1]. Group 1: Shareholder Actions - 南京爱基 has completed its share reduction plan, having reduced approximately 670,000 shares, which represents 0.1314% of the total share capital of about 507 million shares [3]. - The actual number of shares reduced was very close to the planned amount, with a difference of only 25 shares due to unexecuted fractional shares [3]. - Key executives, including the company's vice president and financial director, have also reduced their holdings through 南京爱基, with the total reductions by these individuals being within 25% of their indirect holdings [3].